MIP-3α-SA双功能融合蛋白的制备及其生物学功能鉴定

摘要
图/表
参考文献
相关文章 (3)

全文: PDF (1453 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：制备链亲合素（SA）连接的MIP-3α融合蛋白MIP-3α-SA，并研究其生物学活性及功能。方法：构建MIP-3α-SA-pET21重组表达载体，在大肠杆菌中诱导表达MIP-3α-SA融合蛋白，经镍金属螯合（Ni-NTA）层析纯化，尿素梯度透析复性，聚丙烯酰胺凝胶电泳法（SDS-PAGE）、Western blot及银氨染色法鉴定融合蛋白；通过体外淋巴细胞趋化实验验证其趋化活性，流式细胞术分析其对已生物素化的小鼠前列腺癌RM-1细胞的表面锚定修饰效率。结果：MIP-3α-SA融合蛋白可在大肠杆菌Rosetta（DE3）中实现高效诱导表达，表达量占细菌总蛋白量的30%。经镍柱亲和层析纯化后该融合蛋白纯度达到95%。经尿素梯度复性后，验证该融合蛋白具有双重活性，即：MIP-3α介导的对人淋巴细胞的趋化作用且呈剂量依赖性，及SA介导的高效结合至表面已生物素化的小鼠前列腺癌RM-1细胞的功能（表面锚定修饰效率大于95%）。结论：MIP-3α-SA双功能融合蛋白具有双重活性，为MIP-3α表面锚定修饰的肿瘤细胞疫苗的研制奠定基础。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	宋志纯
	戴数
	王朋
	高基民

关键词 ：巨噬细胞炎性蛋白3&alpha, 链亲和素, 融合蛋白, 锚定修饰

Abstract：Objective: To prepare the streptavidin-tag MIP-3α fusion protein MIP-3α-SA, and to study its biological function and activity. Methods: The recombinant expression vector of MIP-3α-SA-pET21 was constructed and induced to express MIP-3α-SA fusion protein in Escherichia coli. MIP-3α-SA fusion protein was purified by the Ni-NTA affinity chromatography and refolded by gradient dialysis of urea. The fusion protein was identified by amide gel electrophoresis (SDS-PAGE), Western blot and silver ammonia staining. In vitro lymphocyte chemotaxis assays was used to detect the chemotactic activity of the fusion protein, and flow cytometry (FCM) analysis was performed to detect the modification efficiency of the fusion protein on biotin RM-1 cell surface anchoring. Results: The MIP-3α-SA fusion protein expression was induced with high efficiency in E. coli Rosetta (DE3), which accounted for 30% of the total bacterial protein. The purity of the fusion protein was 95% after purification by nickel column affinity chromatography. After renaturation by urea gradient, the fusion protein was verified to have dual activity, namely: MIP-3α-SA stimulated human lymphocyte chemotactic activity has a dose dependent manner and SA-mediated efficient binding to the surface has biotinylated RM-1 cell function (modification of the surface anchoring efficiency of more than 95%). Conclusion: The MIP-3α-SA bifunctional fusion protein has dual activity, which lays the foundation for the research and development of MIP-3α surface-modified tumor cell vaccine.

Key words： macrophage inflammatory protein-3α streptavidin fusion protein anchoring modification

收稿日期: 2018-10-11

基金资助:丽水市科技计划项目（2014JYZB13）。

通讯作者: 高基民，教授，博士生导师，Email：jimingao@yahoo.com。

作者简介: 宋志纯（1979-），女，黑龙江佳木斯人，主管检验师，硕士。

链接本文:

https://xb.wmu.edu.cn/CN/ 或 https://xb.wmu.edu.cn/CN/Y2019/V49/I5/360

[1] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2] 张建. 胃肠道恶性肿瘤的免疫治疗[J]. 临床合理用药, 2016(9): 155-156.
[3] LUGOVIC L, SITUM M, KOS L, et al. Malignant melanoma future prospects[J]. Acta Dermatovenerol Croat, 2005, 13(1): 36-43.
[4] RUBIE C, FRICK VO, GHADJAR P, et al. CCL20/CCR6 expression profile in pancreatic cancer[J]. J Transl Med, 2010, 8: 45.
[5] FUSHIMI T, KOJIMA A, MOORE M A, et al. Macrophage inflammatory protein 3αtransgene attracts dendritic cells to established murine tumors and suppress tumor growth[J].Clin Invest, 2000, 105(10): 1383-1393.
[6] 罗福康, 郑红, 沈大斌, 等. 趋化因子MIP-3α的克隆与表达[J]. 局解手术学杂志, 2005, 14(2): 91-93.
[7] SANO T, CANTOR C R. Streptavidin-containing chimeric proteins: design and production[J]. Methods Enzymol, 2000, 326: 305-311 .
[8] GAO J, HUANG S, LI M, et al. GM-CSF-surface-modified B16. F10 melanoma cell vaccine[J]. Vaccine, 2006, 24(25): 5265-5268.
[9] HE S, WANG L, WU Y, et al. CCL3 and CCL20-recruited dendritic cells modified by melanoma antigen gene-1 induce anti-tumor immunity against gastric cancer ex vivo and in vivo[J]. J Exp Clin Cancer Res, 2010, 29: 37.
[10] ZHANG Z, XU X, ZHANG X, et al. The therapeutic potential of SA-s CD40L in the orthotopic model of superficial bladder cancer[J]. Acta Oncol, 2011, 50(7): 1111-1118.
[11] 徐翠香, 胡志明, 李金龙, 等. SA-TNF-α融合蛋白高效表达、纯化及复性研究[J]. 南方医科大学学报, 2009, 29(3): 412-415.
[12] 张振, 许晓玲, 马磊, 等. 链亲和素标记的白细胞介素4双功能融合蛋白锚定治疗小鼠浅表性膀胱癌[J]. 中华肿瘤杂志, 2012, 34(5): 331-335.
[13] 张振, 贺利民, 马磊, 等. SA-IL-7融合蛋白的制备及其膀胱内灌注对小鼠表浅性膀胱癌的治疗效应[J]. 中国肿瘤生物治疗杂志, 2013, 20(5): 529-534.
[14] 陈惜倩,高基民. SA/h IL24双功能融合蛋白的制备及其生物学活性的鉴定[J]. 温州医学院学报, 2013, 43(2): 78-83.
[15] KUFE D, WEICHSELBAUM R. Radiation therapy: activation for gene transcription and the development of genetic radiotherapy-theapeutic strategies in oncology[J]. Cancer Biol Ther, 2003, 2(4): 326-329.
[16] 邹岚, 朱波, 陈敬, 等. pEgr-MIP-3α重组质粒的构建及其在Lewis肺癌细胞中的辐射诱导表达[J]. 重庆医学, 2004, 33(7): 968.
[17] CAMPBELL A S, ALBO D, KIMSEY T F, et al. Macrophage inflammatory protein-3alpha promotes pancreatic cancer cell invasion[J]. Surgical Res, 2005, 123(1): 96-101.
[18] HU Z, TAN W, ZHANG L, et al. A novel immunotherapy for superficial bladder cancer by intravesical immobilization of GM-CSF[J]. Cell Mol Med, 2010, 14(6B): 1836-1844.
[19] HUANG X, YU H S, CHEN Z, et al. A novel immunotherapy for superficial bladder cancer by the immobilization of streptavidin-tagged bioactive IL-2 on the biotinylated mucosal surface of the bladder wall[J]. Chin J Cancer, 2010, 29(6): 611-616.
[20] ZHANG X, SHI X, LI J, et al. Novel immunotherapy for metastatic bladder cancer using vaccine of human interleukin-2 surface modified MB 49 cells[J]. Urology, 2011, 78(3): 722.e1-6.
[21] SHI X, ZHANG X, LI J, et al. Sequential administration of GM-CSF and IL-2 surface modified MB49 cells vaccines against the metastatic bladder cancer[J]. Urol Oncol, 2013, 31(6): 883-893.